Docetaxel-aconitic anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity
US12419961B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 13, 2022 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | May 16, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F7/1804
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Synthesizing a docetaxel-aconitic anhydride conjugate using docetaxel, including: mixing aconitic anhydride with a chlorinating reagent to produce a first mixture; dissolving the first mixture in an organic solvent to produce a dissolved mixture; stirring the dissolved mixture; evaporating the organic solvent from the dissolved mixture to produce a second mixture; washing the second mixture with an impurity remover to remove impurities and to produce an aconitic anhydride chloride solution; and mixing the docetaxel with the produced aconitic anhydride chloride solution to produce the docetaxel-aconitic anhydride conjugate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.